Malaysia’s Ho Wah Genting Berhad Advises Guardion Health Sciences That It Has received Regulatory Product Registration Appr...
January 28 2021 - 4:15PM
Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the
“Company”), a specialty health sciences company that develops
clinically supported nutrition, medical foods, nutraceuticals and
medical devices, with a focus in the ocular health marketplace,
announced that its exclusive distributor in Malaysia, Ho Wah
Genting Berhad (HWGB), has advised Guardion that Astramern Astra H
(formerly Astramern Nutra H), an immune support dietary supplement
designed and produced by the Company, has been granted product
registration approval by the Malaysian National Pharmaceutical
Regulatory Agency (“NPRA”).
The product registration, which is valid for
five years and is renewable, is an important step toward
commercialization by HWGB. Astramern Astra H comes in capsule form
and contains specifically formulated herbs that are believed to
help boost the body’s immune system.
This product registration approval is the second
such approval received by HWGB using a Guardion-developed product.
In August 2020, the Company announced the product registration
approval of the vitamin formulation Astramern Nutra V. Previously,
in early 2020, HWGB had entered into a Manufacturing and Supply
Agreement for Guardion to design and manufacture both immune
support dietary supplements, which are to be packaged together for
sale by HWGB in Malaysia. HWGB’s healthcare subsidiary, Astramern
Sdn Bhd, has an exclusive license to use and distribute these
products in certain territories. Guardion fulfilled HWGB’s initial
product order of $890,000 in June 2020.
“We have been advised that this product
registration will allow HWGB to package both the Nutra V and Astra
H products together to provide a more complete immune support
product offering to its customers. Importantly, this development
helps to expand Guardion’s presence in the Asian nutraceutical
market,” said Bret Scholtes, President and CEO of Guardion. “A key
part of our strategy includes expansion into foreign markets,
either through licensing, supply and distribution agreements, or
direct marketing opportunities. Additionally, this relationship
with HWGB is important, as it allows the Company to develop new
products that widen our scope in terms of health applications. We
are very pleased to have a leading role in expanding into immune
support in the Asian markets and anticipate a continued expansion
of our product offerings that are supported by verified science and
superior product development.”
About Guardion Health
Sciences
Guardion is a specialty health sciences company
that develops clinically supported nutrition, medical foods,
nutraceuticals and medical devices, with a focus in the ocular
health marketplace. Located in San Diego, California, the Company
combines targeted nutrition with innovative, evidence-based
diagnostic technology. Guardion boasts impressive Scientific and
Medical Advisory Boards. Information and risk factors with respect
to Guardion and its business, including its ability to successfully
develop and commercialize its proprietary products and
technologies, may be obtained in the Company’s filings with the SEC
at www.sec.gov.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. Statements
preceded by, followed by or that otherwise include the words
“believes,” “expects,” “anticipates,” “intends,” “projects,”
“estimates,” “plans” and similar expressions or future or
conditional verbs such as “will,” “should,” “would,” “may” and
“could” are generally forward-looking in nature and not historical
facts, although not all forward-looking statements include the
foregoing. These statements involve unknown risks and uncertainties
that may individually or materially impact the matters discussed
herein for a variety of reasons that are outside the control of the
Company, including, but are not limited to, the Company’s ability
to raise sufficient financing to implement its business plan, the
integration of a new management team, the impact of the COVID-19
pandemic on the Company’s business, operations and the economy in
general, the Company’s ability to successfully develop and
commercialize its proprietary products and technologies, and the
Company’s ability to maintain compliance with Nasdaq’s listing
requirements. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the U.S. Securities and
Exchange Commission (the “SEC”), which are available at the SEC’s
website (www.sec.gov). The Company disclaims any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Investor Relations Contact:CORE
IRScott Arnold516-222-2560scotta@coreir.com
Media Relations Contact:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024